Sinaptica Therapeutics develops non-invasive neuromodulation systems designed to slow the progression of Alzheimer’s disease through personalized brain network targeting. The company’s platform, SinaptiStim, combines repetitive transcranial magnetic stimulation (rTMS) with electroencephalography (EEG) to deliver individualized therapy. Its approach focuses on modulating large-scale brain networks implicated in neurodegeneration rather than stimulating fixed anatomical sites. Sinaptica Therapeutics positions its technology within regulated clinical development pathways.

The technology integrates EEG-based assessment with rTMS to identify and target patient-specific network dysfunction, particularly within the default mode network. Closed-loop protocols use neural signals to guide stimulation parameters and timing, enabling adaptive intervention based on individual brain activity. This combined sensing-and-stimulation framework is designed to improve precision and consistency of neuromodulation. Clinical studies have demonstrated efficacy in modulating network activity relevant to Alzheimer’s disease.

Sinaptica Therapeutics targets patients with Alzheimer’s disease, focusing on slowing cognitive decline and disease progression. The SinaptiStim system is intended for use in clinical trial and therapeutic settings under professional supervision. Its positioning reflects broader movement toward network-level, personalized neuromodulation approaches in neurodegenerative disease treatment.